Healthcare
Commented by Fabian Lorenz on September 12th, 2025 | 07:15 CEST
200% shares Steyr Motors and PanGenomic Health! When will cancer-fighter BioNTech explode?
More than 200% price gains are not enough: Steyr Motors and PanGenomic Health continue to go full throttle. Despite its strong performance in recent weeks, PanGenomic still appears undervalued. With the use of artificial intelligence, the Canadians want to tap into the billion-dollar market for personalized alternative medicine and dietary supplements in North America. Their e-commerce platform has just gone live. Steyr Motors reports several successes in China, opening up a billion-dollar market for the Austrians. In contrast, BioNTech shares are not moving. Yet the Mainz-based company is increasingly becoming a real cancer fighter. Will the stock soon explode?
Read
Commented by André Will-Laudien on August 26th, 2025 | 07:20 CEST
Big moves! Buying frenzy at Novo Nordisk and PanGenomic Health, Valneva left behind
Things are moving again in the biotech sector! While Novo Nordisk appears to have finally found its footing after three profit warnings, PanGenomic Health continues its upward trend. Since launching its new business model in May, the stock has staged a phenomenal rally of over 1,000%. Meanwhile, Valneva faces a major setback as the US Food and Drug Administration (FDA) has halted approval of the chikungunya vaccine Ixchiq due to severe side effects. This comes as a shock to investors, who are now waiting for the Company to provide further explanations. The stock market has reacted with a sharp drop in the share price. How can investors benefit from the current situation?
Read
Commented by Nico Popp on August 18th, 2025 | 07:25 CEST
780% return thanks to expensive medicine: PanGenomic Health, CVS Health, Teladoc Health
Healthcare costs are skyrocketing. According to KFF, a leading US healthcare policy organization, the United States spent around USD 4.5 trillion on healthcare in 2022. That is equivalent to 17% of gross domestic product. Given the millions of Americans who, due to lack of insurance, opt for painkillers instead of visiting a dentist, that is a remarkable figure. KFF also reports that one in four Americans postponed medical treatment last year. In this complex environment, the importance of personal responsibility and self-therapy is growing. Companies are stepping in to address the situation and offer solutions. We present three business models and explain what opportunities they may hold for investors.
Read
Commented by André Will-Laudien on July 30th, 2025 | 07:00 CEST
Trump's Tariffs & Takeovers! BioNTech, PanGenomic Health, Pfizer, and Valneva Targeted by Speculators
The US-EU tariff agreement has now been finalized. Many sectors of the European economy will now face additional burdens and margin cuts. The biotech and pharmaceutical industries have been spared, as medicines and active pharmaceutical ingredients are among the few product groups that are traditionally traded duty-free in transatlantic trade. This is due to international agreements, such as the WTO Pharmaceutical Agreement, which both the EU and the US have signed. Clinical trial drugs, active ingredient imports, and vaccines are also mostly exempt from tariffs. Valneva is currently making headlines with its chikungunya vaccine, BioNTech and Pfizer are continuing to sell COVID-19 vaccines on a small scale, and PanGenomic is surprising everyone with a new AI-powered health platform. A lot is going on in the sector – who are the big earners?
Read
Commented by Nico Popp on July 24th, 2025 | 07:10 CEST
No high-tech without tungsten – This bottleneck brings returns: Almonty, Siemens Healthineers, Intel
Tungsten is known as a defense metal due to its hardness and heat resistance. But it is also one of the invisible drivers of the high-tech industry. Using examples from medical technology and chip manufacturing, we explain why tungsten is rightly considered a key element in the future of raw material supply. We also venture a long-term outlook on the potential of tungsten producer Almonty Industries' stock.
Read
Commented by Nico Popp on July 21st, 2025 | 07:15 CEST
A turning point in German healthcare! Are we moving closer to the US model? PanGenomic Health, Bayer, and Nestlé
Are US-style conditions soon coming to Germany? Health economist Jürgen Wasem is calling for greater patient cost-sharing. Certain medications could be made available over the counter, allowing patients to access them more easily at their own expense. This could help reduce costs. This form of self-medication has long been common in the US, where people with certain ailments naturally turn to over-the-counter preparations or potent health foods. How can investors benefit from this trend? We present the shares of Bayer, Nestlé, and PanGenomic Health!
Read
Commented by Fabian Lorenz on July 16th, 2025 | 07:25 CEST
WINNING STOCKS for the second half of the year!? Rheinmetall, Bayer, and Hotstock PanGenomic Health
Hard to believe: Bayer shares are among the winners in 2025. And even the news flow is positive. Does the Leverkusen-based company even have a new blockbuster in the pipeline? What do analysts say? PanGenomic Health shares could be among the stars of the second half of the year. With a new health app, the Company is entering a billion-dollar market in the US and benefiting from the Trump administration. If it succeeds in securing market share, the stock should have plenty of upside potential. Analysts believe that the air is getting thinner for Rheinmetall shares. However, it is likely only a matter of time before the EUR 2,000 mark is broken.
Read
Commented by Armin Schulz on July 16th, 2025 | 07:10 CEST
Novo Nordisk, BioNxt Solutions, BioNTech – How to heal your portfolio with the 2025 healthcare revolution
The global healthcare system is facing a turning point in 2025. Climate change, chronic diseases, and the scars left by pandemics are challenging existing systems, while digitalization and AI are rapidly advancing new therapies. Governments are investing billions in modern healthcare infrastructure, but debates about data protection and scheduling doctor's appointments are escalating. While the WHO warns of stagnation, groundbreaking alliances between research and industry are emerging. This is precisely where Novo Nordisk, BioNxt Solutions, and BioNTech come in with visionary technologies that not only heal but also open up opportunities for investors.
Read
Commented by Armin Schulz on June 24th, 2025 | 07:30 CEST
Portfolio Doubler with Artificial Intelligence: Novo Nordisk, PanGenomic Health, and Pfizer Ignite the Profit Growth in 2025
According to BlackRock Health Sciences, the global healthcare sector is poised for an unprecedented boom in 2025. After years of volatility driven by the pandemic, the industry is now expected to achieve its highest profit growth in almost two decades - and across the board, not just among pandemic-driven outliers. Digital revolutions such as AI-assisted drug development and telemedicine are accelerating change and creating radically new business models. Those who understand the architects of this transformation will recognize the growth drivers of tomorrow. With this in mind, we take a closer look at three key companies: Novo Nordisk, PanGenomic Health, and Pfizer.
Read
Commented by Nico Popp on June 10th, 2025 | 07:20 CEST
Future market – Worth about USD 50 billion: Illumina, Moderna, PanGenomic Health
Medicine is becoming personal. The era of one-size-fits-all drugs is coming to an end. Experts at BCC Research predict that the market for personalized medicine will grow from USD 54.2 billion in 2023 to USD 100.5 billion by 2028. That represents an annual growth rate of 13.2%. Other analysis firms, such as Grand View Research and Market Research Intellect, confirm this promising outlook for investors. All the more reason to take a closer look at Illumina, Moderna, and PanGenomic Health and explore the opportunities they present for investors.
Read